Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial

NCT04845971 is registered in ClinicalTrials.gov with Dr. Spadera Lucrezia as lead sponsor.

NCT NCT04845971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04845971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial
Lead sponsor
Dr. Spadera Lucrezia
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2020
Completion date
June 30, 2021
Enrollment
97 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia